期刊论文

中文

中国肿瘤临床

1000-8179

2000

27

4

262-264

湖南省科委科研基金；

本校为第一机构

目的 :探讨mdm2癌基因蛋白在骨巨细胞瘤 （GCT）的表达及与GCT病理分级和临床良恶性的关系。方法 :应用SP免疫组织化学方法检测mdm2在 5 2例GCT（GCT按Jaffe分级 :Ⅰ级 15例、Ⅱ级 2 5例、Ⅲ级 12例 ）中的表达。结果 :18例mdm2表达呈阳性 ,占 34 .6 % ,在Ⅰ～Ⅲ级中的阳性表达率分别为 40 .0 %、32 .0 %、33.3% ,mdm2阳性表达率在骨巨细胞瘤Ⅰ～Ⅲ级中的差异无显著性意义 （χ2 =0 .2 8,P >0 .0 5 ）。在良性、可疑恶性和恶性中的阳性表达分别为 15 .0 %、35 .3%、6 0 .0 % ,mdm2阳性表达率在骨巨细胞瘤良恶性中的差异有显著性意义 （χ2 =7.6 7,P

Objective: To investigate the relationship of mdm2 protein overexpression with pathological types and prognosis of human giant cell tumor of bone. Methods: Monoclonal antibodies directed against mdm2 proteins were used to measure the expression of these proteins in the nuclear of cells from the sections of giant cell tumor of bone. Results: Eighteen of 52 tumors expressed mdm2 protein. According to Jaffe's grading the positive percentages of grade Ⅰ , grade Ⅱ and grade Ⅲ giant cell tumors of bone were 40% , 32% and 33.3% respectively. A posi...